The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends
Abstract
The safety of blood transfusion is still threatened by contamination of blood products with a variety of pathogens such as viruses, bacteria and parasites. A novel pathogen reduction process for platelets and plasma products, the Mirasol PRT system, has been developed and is under clinical evaluation for its efficacy and safety. The Mirasol PRT process is based on riboflavin photochemistry. This manuscript reviews current progress and future trends.
Keywords: Riboflavin, Pathogen inactivation, Blood safety, Transfusion medicine
To access this article, please choose from the options below
PII: S1473-0502(06)00085-1
doi:10.1016/j.transci.2006.01.007
© 2006 Elsevier Ltd. All rights reserved.
